PENTETATE CALCIUM TRISODIUM
POST RADIATION EXPOSURE TREATMENTS · EXPOSURE TO PLUTONIUM RADIATION ·+2
HAMELN-GSMS
Drug class
Post Radiation Exposure Treatments
Post radiation exposure treatments are not a single pharmacological class, but rather a functional category of medical countermeasures and supportive therapies administered after exposure to ionizing radiation or internal radionuclide contamination. Read more about Post Radiation Exposure Treatments
2 drugs in this class 1 manufacturers
Drugs in Post Radiation Exposure Treatments
PENTETATE ZINC TRISODIUM
POST RADIATION EXPOSURE TREATMENTS · EXPOSURE TO PLUTONIUM RADIATION ·+2
HAMELN-GSMS
Filter & compare in the drug finder →
Opens the drug finder with Post Radiation Exposure Treatments preselected. Add indication or manufacturer filters there.
Post radiation exposure treatments are not a single pharmacological class, but rather a functional category of medical countermeasures and supportive therapies administered after exposure to ionizing radiation or internal radionuclide contamination.
Their mechanisms vary widely: hematopoietic growth factors and thrombopoietin receptor agonists stimulate bone marrow recovery to treat radiation-induced myelosuppression, whereas blocking or decorporation agents—such as potassium iodide, Prussian blue, and chelators—prevent uptake or accelerate clearance of radioactive isotopes.
These interventions are primarily indicated for emergency preparedness and management of acute radiation syndrome, delayed radiation injuries, and internal contamination following radiological or nuclear incidents.
-
fda.gov
Post radiation exposure treatments are not a single pharmacological class, but rather a functional category of medical countermeasures and supportive therapies administered after exposure to ionizing radiation or internal radionuclide contamination Their mechanisms vary widely: hematopoietic growth factors and thrombopoietin receptor agonists stimulate bone marrow recovery to treat radiation-induced myelosuppression, whereas blocking or decorporation agents—such as potassium iodide, Prussian blu...
-
nih.gov
Post radiation exposure treatments are not a single pharmacological class, but rather a functional category of medical countermeasures and supportive therapies administered after exposure to ionizing radiation or internal radionuclide contamination Their mechanisms vary widely: hematopoietic growth factors and thrombopoietin receptor agonists stimulate bone marrow recovery to treat radiation-induced myelosuppression, whereas blocking or decorporation agents—such as potassium iodide, Prussian blu...
-
fda.gov
Their mechanisms vary widely: hematopoietic growth factors and thrombopoietin receptor agonists stimulate bone marrow recovery to treat radiation-induced myelosuppression, whereas blocking or decorporation agents—such as potassium iodide, Prussian blue, and chelators—prevent uptake or accelerate clearance of radioactive isotopes These interventions are primarily indicated for emergency preparedness and management of acute radiation syndrome, delayed radiation injuries, and internal contamination...
-
nih.gov
Their mechanisms vary widely: hematopoietic growth factors and thrombopoietin receptor agonists stimulate bone marrow recovery to treat radiation-induced myelosuppression, whereas blocking or decorporation agents—such as potassium iodide, Prussian blue, and chelators—prevent uptake or accelerate clearance of radioactive isotopes
-
fda.gov
These interventions are primarily indicated for emergency preparedness and management of acute radiation syndrome, delayed radiation injuries, and internal contamination following radiological or nuclear incidents
-
umaryland.edu
These interventions are primarily indicated for emergency preparedness and management of acute radiation syndrome, delayed radiation injuries, and internal contamination following radiological or nuclear incidents
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.